If loss of PTEN is frequent among EGFR-positive cancer, then this may be a contributing factor to the significant resistance to EGFR inhibitors seen in the clinic [16] and further stresses the potential importance of combination therapies against both EGFR/MAPK and PTEN/PI3K/AKT signaling pathways. Here, AKT1 is linked to cancer.